// App-Quantinova.ai

5537 : Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).

Researchers

Presenter

  • Tanya Kwan

Principal Investigators

  • Domenica Lorusso

  • Carol Aghajanian

  • Ana Oaknin

  • Andrew Peter Dean

  • Nicoletta Colombo

  • Johanne I Weberpals

  • Giovanni Scambia

  • Alexandra Leary

  • Robert W. Holloway

  • Margarita Amenedo

  • Peter C.C. Fong

  • Jeffrey C. Goh

  • David M. O'Malley

  • Lara Maloney

  • Sandra Goble

  • Jonathan A. Ledermann

  • Robert L. Coleman

  • Andrew R. Clamp

Medical Centers

  • Clovis Oncology, Inc., Boulder, CO, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

  • Memorial Sloan Kettering Cancer Center, New York, NY, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

  • St. John of God Hospital, Subiaco, Australia

  • University of Milano-Bicocca and European Institute of Oncology, Milano, Italy

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Rome, Italy

  • Gustave Roussy Cancer Center, INSERM U981, and Groupe D'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, France

  • Florida Hospital Cancer Institute, Orlando, FL, Oncology Center of Galicia, La Coruña, Spain

  • Auckland City Hospital and University of Auckland, Auckland, New Zealand

  • Cancer Care Services, Royal Brisbane and Women’s Hospital, Herston, Australia

  • University of Queensland, St. Lucia, Australia

  • The Ohio State University, James Cancer Center, Columbus, OH, UCL Cancer Institute, University College London and UCL Hospitals, London, United Kingdom

  • Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

Locations

  • Canada

  • Italy

  • Spain

  • Australia

  • France

  • New Zealand

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

Drug/Treatment

  • Rucaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • NCT01968213

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved